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Odontogenic tumors (OTs) are lesions that derived
from the tooth-producing tissues or their remnants that
remain entrapped either within the jawbones or into the
adjacent soft tissues [1].
The odontogenic keratocyst (OKC) differs from
other cysts; it shows more aggressive clinical behavior,
demonstrates a high mitotic count and high epithelial
turnover rate.* Corresponding author.
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Peer review under the responsibility of the Faculty of Dentistry, Tanta
University
Production and hosting by Elsevier
1687-8574  2013, Production and Hosting by Elsevier B.V. on behalf of
http://dx.doi.org/10.1016/j.tdj.2013.12.0Open access under CC BY-NC-ND license.In the years since, published reports have influenced
WHO to reclassify the lesion as a tumor. Several fac-
tors form the basis of this decision; the OKC is locally
destructive and highly recurrent, the basal layer of the
OKC budding into connective tissue with high mitotic
figures are frequently found in the suprabasal layers [2]
and patched-1 gene mutation [3].
KCOTs comprise approximately 11% of all cysts of
the jaws [4,5]. It has a slight male predilection and
commonly occurs in the second and third decades of
life [6]. They occur most commonly in the mandible,
especially in the posterior body and ramus regions.
They usually occur within bone, although a small
number of cases of peripheral KCOT have been re-
ported [7].
Histological features are characterized by the pres-
ence of a thin band like parakeratinized or orthoker-
atinized stratified squamous epithelium, with a
prominent basal layer composed of either columnar orthe Faculty of Dentistry, Tanta University.
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usually free of inflammation [8,9].
KCOTs have a high recurrence rate, reportedly be-
tween 25% and 60% [10], when associated with nevoid
basal cell carcinoma syndrome, the recurrence rate is
about 82% [11].
The aggressive nature of KCOTwarrants an aggres-
sive treatment strategy [12]. Resection of the jaw results
in the lowest recurrence rate [13]. However, considering
the radical nature of the procedure, unless resection is
necessary, it is acceptable to use enucleation in combi-
nation with Carnoy’s solution or marsupialization [14].
Perlecan (Pln), originally named heparin sulfate
proteoglycan-2, is a large multidomain proteoglycan
that is widely distributed in the vascular basement
membranes (BMs) [15] and in some connective tissues
that lack classical BMs, such as cartilage matrix and
sinusoids of liver, spleen and lymph nodes [16,17].
Proteoglycans are thought to govern the process of
cell movement in numerous physiological and patho-
logical conditions, spanning from early embryonic
development to tumor invasion and metastasis [18,19].
Perlecan supports various biological functions,
including cell adhesion (mainly to fibroblasts and
endothelial cells), modulation of apoptosis, epidermal
formation, chondrogenesis, lipid catabolism and plays a
major role in migration, proliferation, adhesion and
regulation of growth factor activities especially vascular
endothelial growth factor and fibroblast growth factor 2
[20]. It can act as a reservoir or modulator of growth
factor function leads to the autocrine growth of the tumor
and neovascularization. Thus, perlecan is a potent
modulator of cell growth [21,22].
The present evidence of perlecan deposition in the
intercellular space of the stellate reticulummay indicate
that it acts as a carrier for transport of nutrients to
epithelial cells for enamel formation because no nutrient
supplies can be expected from the dental papilla side
because of the presence of dental hard matrices [23,24].
Perlecan has been shown to be localized in the in-
flammatory tissues in oral cavity [25], in the myxo-
matous stroma of granulation tissues and in squamous
epithelial dysplasia of the oral mucosa [26,27].
Syndecan molecules are single transmembrane
domain proteins that belong to the heparan sulfate
proteoglycan family. Four members of the syndecan
family have been identified and include syndecan-1, -2,
-3, and -4. The best-known member of the syndecan
family, which has been extensively studied, is
syndecan-1 that is also called CD138 [28]. It is a
glycoprotein of 150e250 kDa expressed by simple
epithelial cells, stratified epithelial cells, mesenchymalcells as vascular smooth muscle cells, endothelial cells,
lymphocytes and plasma cells [29].
Syndecans are cell surface adhesive molecules
involved in cellecell adhesion and interactions with
the extracellular matrix and are capable of binding
several ligands as matrix components, growth factors
especially basic fibroblast growth factor which is a
potent angiogenic growth factor, heparin binding fac-
tors, degradative enzymes, protease inhibitors and
some serum proteins [30,31].
Syndecan is suggested to function as matrix recep-
tor transducting information between the extracellular
matrix and the inside of the cell. At the cell surface, it
serves as coreceptor that catalyzes the interaction be-
tween ligands and their respective signaling receptors
increasing ligand concentration so regulates recep-
toreligand interactions [32].
Cell proliferation is regarded as one of the most
important biological mechanisms in oncogenesis [33]. A
surveyof the results ofa largenumberof studies has shown
that the proliferative activity is of high prognostic signif-
icance in several types of tumors. The assessment of the
presence of cell cycle-related protein may yield important
information about the biological behavior of a tumor [34].
Among the proliferation markers, Ki-67 has been
considered to be a potent tool for making an easy and
quick evaluation of the growth fraction [35]. The
expression of Ki-67 varies in intensity throughout the
cell cycle. Ki-67 levels are low during G- and early S-
phase and progressively increase to reach a maximum
during mitosis. A rapid decrease in expression starts
during anaphase and telophase [36,37].
So,Ki-67 antigen,whichmay be detected in all stages
of the cell cycle except G0, represents a marker associ-
ated with tumor proliferation, invasiveness, and ulti-
mately prognosis [38]. So, Ki-67 is used in evaluating
cellular proliferation rates of malignant tumors [39].
The aim of the present work is to investigate the
expression and the distribution pattern of perlecan,
syndecan-1 and ki-67 immuno-histochemically in
keratocystic odontogenic tumor. To correlate the clin-
ical and histological features of keratocystic odonto-
genic tumor with the immunohistochemical expression
of these markers to clarify their role in the biological
behavior of this tumor (Table 1).
2. Materials and methods
The present study included twenty biopsy speci-
mens from keratocystic odontogenic tumor. Detailed
case history and thorough clinical examination were
performed for each case.
Table 1
Expression of perlecan, syndecan-1 (CD138) and Ki-67 in kerato-
cystic odontogenic tumor.
Odontogenic keratocyst Total
-ve þ þþ þþþ
Perlecan N e e 12 8 20
% e e 60 40 100
Syndecan-1 N e e 8 12 20
% e e 60 40 100
Ki-67 N e 4 16 e 20
% e 20 80 e 100
Total N 1 1 12 11 25
% 4 4 48 44 100
X2 1.552
p value 0.062
Fig. 1. A microscopical picture of keratocystic odontogenic tumor
showing uniform thickness of the epithelial lining of the cyst with
palisaded basal cells (H&E, 100).
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genic tumors were fixed in 10% neutral buffered
formalin and routinely processed for hematoxylin and
eosin (H&E) and examined under light microscope.
For immunohistochemical (IHC) study, the Avi-
dineBiotin Complex (ABC) technique was used to
detect the following reagents:
Primary antibodies against Perlecan (Clone: A7L6,
Mouse monoclonal), Syndecan CD138 (Clone: MI15,
Mouse monoclonal) and Ki67 (Clone: SP6, Rabbit mono-
clonal). The antibodies used and their associated kit and
reagentswereobtained fromLabvision,FremontCA,USA.
The immunostaining procedure was performed ac-
cording to the manufacturer instructions. The depar-
affinized sections associated with immunostaining kit
were processed acting as positive controls whereas
negative controls consisting of tissue sections on which
primary antibody was replaced with nonimmune serum
was also performed.
Assessment of the staining intensity and number of
positive cells was performed as follow: A section was
considered either positive or negative according to the
presence or absence of brown staining in the cytoplasm or
cell membrane of tumor cells; regarding perlecan and
CD138 analysis, and in nuclei of tumor cells regardingKi-
67 analysis. Two independent pathologists counted the
number of positive cells in (þ) cases. A mean percentage
of positive tumor cellswas determined by the examination
of tumor cells in at least five areas at 400magnification.
The intensity of perlecan, syndecan-1 and Ki-67
were graded separately as follow:
strongð þþþ Þ;moderateð þþÞ;mildð þ Þ and
negativeð  Þ:
Statistical presentation and analysis of the present
study was conducted, using chi-square test by SPl8SS
V.16 and Chi-square test.3. Results
3.1. Conventional hematoxylin and eosin staining
(H&E)
All cases showed a cystic cavity, the epithelial lin-
ing was composed of a uniform layer of stratified
squamous epithelium from six to eight cells in
thickness.
The basal epithelial layer was composed of a pali-
saded layer of cuboidal or columnar epithelial cells
which were often hyperchromatic (Fig. 1). The luminal
surface showed superficial parakeratotic epithelial cells
which present a wavy or corrugated appearance.
The epithelial e connective tissue interface walls
flat and rete ridges formation was inconspicuous.
Detachment of portions of the cyst lining epithelium
from the fibrous capsule was commonly observed.
The fibrous capsule showed mild inflammatory cells
infiltration.
3.2. Immunoreactivity to perlecan
In the cyst lining of keratocystic odontogenic tu-
mors, perlecan was immunolocalized mainly on the
cell border of squamous epithelial cells from the basal
cell layer to higher levels (Fig. 2). 8 out of 20 cases
(40%) showed strong diffuse cytoplasmic staining
while the other twelve cases (60%) showed moderate
cytoplasmic staining.
Fig. 3. A microscopical picture of syndecan-1 (CD138) immuno-
staining in keratocystic odontogenic tumor showing strong diffuse
cytoplasmic staining of the all thickness of the epithelial lining
(CD138, 100).
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Syndecan-1 (CD138) expression was considered
positive when immunoreactivity was unequivocally
observed in the cell membrane and/or cytoplasm as
brown staining (Fig. 3).
12 out of 20 cases (60%) showed strong diffuse
cytoplasmic staining so all the thickness of the
epithelial lining showed strong positive CD138
expression. 8 out of 20 cases (40%) showed moderate
cytoplasmic staining.
The inflammatory cells in the connective tissue
capsule also showed positivity to CD138 (Fig. 4).
3.4. Immunoreactivity to Ki-67
The suprabasal cells showed positivity to Ki-67
(Fig. 5). 16 out of 20 cases (80%) showed moderate
nuclear staining mainly in suprabasal epithelial cells.
And 4 out of 20 cases (20%) showed mild (weak)
nuclear staining. Some inflammatory cells land fibro-
blasts in the fibrous tissue capsule showed positive Ki-
67 staining (Figs. 6,7).
4. Discussion
In this study, it was noted that perlecan was
immunolocalized mainly in squamous epithelial cells
from the basal cell layer to higher levels supported the
previous observation of Iozzo 2005 [40] that demon-
strated the first study of the definite intercellularFig. 2. A microscopical picture of Perlecan immunostaining in
keratocystic odontogenic tumor was localized strongly in the cell
border from basal cells to the surface (perlecan, 400).deposition of perlecan within the lining epithelium of
keratocystic odontogenic tumor.
Tsuneki et al., 2008 [41] examined the intra-
epithelial deposition of perlecan in keratocystic odon-
togenic tumor, dentigerous cysts and radicular cysts.
They found that, in keratocystic odontogenic tumor
perlecan was localized on the cell border from the
parabasal to subkeratinized layers of the lining
epithelium. In contrast to keratocystic odontogenicFig. 4. A microscopical picture of the inflammatory cells in the
fibrous connective tissue capsule showed positivity to syndecan-1
(CD138, 40).
Fig. 5. A microscopical picture of Ki-67 immunostaining in kera-
tocystic odontogenic tumor showing moderate nuclear staining of the
suprabasal cells of the epithelial lining (Ki 67, 200).
Fig. 7. Expression of perlecan, syndecan-1 (CD138) and Ki-67 in
keratocystic odontogenic tumor.
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perlecan, this new evidence supporting the neoplastic
nature of keratocystic odontogenic tumor.
In the present study, in areas of inflammation as in
connective tissue fibrous capsule, perlecan was also
expressed in almost all the inflammatory cells. This
finding was also reported by Christopher 2006 [42]
who supported the important role of perlecan in
inflammation.Fig. 6. A microscopical picture of some fibroblasts and inflammatory
cells in the fibrous capsule showed positive Ki-67 staining (Ki 67,
100).Expression of perlecan in lining of odontogenic
keratocyst support the results of Ida-Yonemochi and
Saku [25], Knox and Whitelock [43], Farach-Carson
and Carson [15] who concluded that the function of
perlecan as a reservoir for several kinds of growth
factors which is necessary in the proliferation and
differentiation of the lining cells and in growth of
keratocystic odontogenic tumor [40].
In KCOT, in areas of typical epithelial lining, high
and intense expression of syndecan-1 was maintained
even in the presence of inflammatory cells. This
finding agrees with that of Regina et al., 2011 [44] who
found expression of syndecan-1 in the inflammatory
cells of radicular cyst, dentigerous cyst and kerato-
cystic odontogenic tumor that presented secondary
inflammation. They also added that syndecan-1 seems
be essential for maintaining the epithelial morphology
and eventually controlling the cytoskeletal organiza-
tion of the epithelial lining in odontogenic cystic
lesions.
KCOT has been found to have a relatively high
proliferation index which was in accordance with Kimi
et al., 2000 [45] Shear 2002 [46], Kimi et al., 2001
[47], Kim et al., 2003 [48], Thosaporn et al., 2004 [49],
Kichi et al., 2005 [50] and may well be related to the
distinct growth mechanism of these lesions.
Mateus et al., 2008 [51] and Mendes et al., 2010
[52] found that the proliferative index was higher in
keratocystic odontogenic tumors than in dentigerous
cysts. The high proliferative activity of the keratocystic
odontogenic tumor epithelial lining is pinpointed as its
main growth mechanism which supports its classifi-
cation as an odontogenic tumor.
Lo Muzio et al., 1999 [53] and Nadalin et al., 2011
[54] showed that the proliferative center of the kera-
tocystic odontogenic tumor epithelial lining is the
suprabasal layer and so this epithelial lining presents a
158 O.M. Wahba et al. / Tanta Dental Journal 10 (2013) 153e159different pattern of cell proliferation and differentiation
demonstrating its high cell turnover and reinforcing its
classification as an odontogenic tumor as well Shear
2002b [55] and Clarissa et al., 2008 [56] found that
Ki67 can be used as a marker contribute to the biologic
profile of keratocystic odontogenic tumor.
From the results of the present study, there is a
diverse correlation between perlecan, syndecan-1 as a
group and ki-67. Over expression of ki-67 with
decrease in perlecan and/or syndecan-1 may be
markers for the aggressiveness and the biological
behavior of the keratocystic odontogenic tumor. The
key element of future management of keratocystic
odontogenic tumor will probably be based on thorough
knowledge of the biological basis of this tumor,
thereby enabling a more tailored treatment approach.
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